Cargando…
Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis
We conducted a retrospective data analysis of 26 patients with chronic spontaneous urticaria (CSU), 12 of whom had been treated with anti-IgE therapy (omalizumab). The subcohort of patients treated with omalizumab displayed more severe and prolonged courses of disease. In addition, they had often un...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215321/ https://www.ncbi.nlm.nih.gov/pubmed/35925212 http://dx.doi.org/10.1007/s00105-022-05023-3 |
_version_ | 1784731184879632384 |
---|---|
author | Diamanti, Evangelia Föhr, Julia Papageorgiou, Andria Herbst, Matthias Jahn, Sigbert |
author_facet | Diamanti, Evangelia Föhr, Julia Papageorgiou, Andria Herbst, Matthias Jahn, Sigbert |
author_sort | Diamanti, Evangelia |
collection | PubMed |
description | We conducted a retrospective data analysis of 26 patients with chronic spontaneous urticaria (CSU), 12 of whom had been treated with anti-IgE therapy (omalizumab). The subcohort of patients treated with omalizumab displayed more severe and prolonged courses of disease. In addition, they had often undergone various inpatient therapies, frequently presenting with concomitant angioedema. Collecting the Urticaria Activity Scores from the seven daily values for wheals and itching (UAS7) proved an important and suitable instrument for the determination and assessment of the course of therapy in the dermatological office. Elaborate laboratory screenings, however, seem far less indicative of the severity, prognosis and course of the disease. Omalizumab proved to be a viable and well-tolerated treatment option. One third of the patients were completely free of all symptoms, another third showed very good improvement, whereas the last third showed no improvement at all, even when omalizumab and/or concomitant therapies were escalated. |
format | Online Article Text |
id | pubmed-9215321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-92153212022-06-22 Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis Diamanti, Evangelia Föhr, Julia Papageorgiou, Andria Herbst, Matthias Jahn, Sigbert Dermatologie (Heidelb) Originalien We conducted a retrospective data analysis of 26 patients with chronic spontaneous urticaria (CSU), 12 of whom had been treated with anti-IgE therapy (omalizumab). The subcohort of patients treated with omalizumab displayed more severe and prolonged courses of disease. In addition, they had often undergone various inpatient therapies, frequently presenting with concomitant angioedema. Collecting the Urticaria Activity Scores from the seven daily values for wheals and itching (UAS7) proved an important and suitable instrument for the determination and assessment of the course of therapy in the dermatological office. Elaborate laboratory screenings, however, seem far less indicative of the severity, prognosis and course of the disease. Omalizumab proved to be a viable and well-tolerated treatment option. One third of the patients were completely free of all symptoms, another third showed very good improvement, whereas the last third showed no improvement at all, even when omalizumab and/or concomitant therapies were escalated. Springer Medizin 2022-06-22 2022 /pmc/articles/PMC9215321/ /pubmed/35925212 http://dx.doi.org/10.1007/s00105-022-05023-3 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Originalien Diamanti, Evangelia Föhr, Julia Papageorgiou, Andria Herbst, Matthias Jahn, Sigbert Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis |
title | Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis |
title_full | Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis |
title_fullStr | Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis |
title_full_unstemmed | Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis |
title_short | Anti-IgE-gerichtete Therapie der Urtikaria in der dermatologischen Praxis |
title_sort | anti-ige-gerichtete therapie der urtikaria in der dermatologischen praxis |
topic | Originalien |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215321/ https://www.ncbi.nlm.nih.gov/pubmed/35925212 http://dx.doi.org/10.1007/s00105-022-05023-3 |
work_keys_str_mv | AT diamantievangelia antiigegerichtetetherapiederurtikariainderdermatologischenpraxis AT fohrjulia antiigegerichtetetherapiederurtikariainderdermatologischenpraxis AT papageorgiouandria antiigegerichtetetherapiederurtikariainderdermatologischenpraxis AT herbstmatthias antiigegerichtetetherapiederurtikariainderdermatologischenpraxis AT jahnsigbert antiigegerichtetetherapiederurtikariainderdermatologischenpraxis |